Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 267 | 0.70 |
| pathways Reactome | 3 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 8870
Sealed predictions
- OMA1 in dopamine neurons, braak-0.05 (p 0.893) → -0.30 (p 0.435)receipt 8876
Swarm cases
receipt 8876: OMA1 in dopamine neurons, braak
- power
- full sample -0.15 (p 0.555, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.13 (p 0.609, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.31 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.555, n 18). fragile.
- cell type
- strongest in OPCs: +0.64 (p 0.0040, n 18) vs -0.15 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OMA1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up OMA1 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.38 p 0.183 (needs p < 2.4e-4)
Receipts
loading the receipts